Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


 Company News
Boehringer Ingelheim Release: Type 2 Diabetes: Synjardy (Empagliflozin/Metformin Hydrochloride) Approved In The European Union 5/28/2015 10:34:33 AM
Boehringer Ingelheim And Lilly Diabetes Alliance To Present Data From 35 Studies At The American Diabetes Association's 75th Scientific Sessions 5/27/2015 9:45:49 AM
Boehringer Ingelheim Grabs FDA Approval for Next-Gen COPD Drug 5/26/2015 8:16:50 AM
Eureka Therapeutics And Boehringer Ingelheim Announce A Collaboration To Identify Next Generation Antibodies For Cancer Treatment 5/22/2015 8:52:26 AM
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015 11:36:24 AM
Boehringer Ingelheim Release: New Data Analyses On Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared To Tiotropium And Olodaterol Alone 5/20/2015 11:05:32 AM
Boehringer Ingelheim Acquires Pharmaxis (PXS.AX)’ Phase 1 Anti-Inflammatory Drug Candidate 5/18/2015 11:08:03 AM
Boehringer Ingelheim Presents New Data And Analyses Reinforcing The Safety And Efficacy Of OFEV (nintedanib) Capsules 5/18/2015 6:46:15 AM
Pharmaxis (PXS.AX) Shares Catapult on $750 Million Liver Drug Sale to Boehringer Ingelheim 5/18/2015 6:09:16 AM
Boehringer Ingelheim Showcases Expanding Presence In Lung Cancer At ASCO With New Data Including Presentation Of Gilotrif (Afatinib) Overall Survival Results For Squamous Cell Carcinoma Of The Lung 5/14/2015 11:23:26 AM